- Home
- STG vs PRLD Comparison
STG vs PRLD Comparison
Compare STG & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STG
- PRLD
- Stock Information
- Founded
- STG 2003
- PRLD 2016
- Country
- STG China
- PRLD United States
- Employees
- STG N/A
- PRLD N/A
- Industry
- STG Other Consumer Services
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- STG Real Estate
- PRLD Health Care
- Exchange
- STG Nasdaq
- PRLD Nasdaq
- Market Cap
- STG 91.6M
- PRLD 73.7M
- IPO Year
- STG 2018
- PRLD 2020
- Fundamental
- Price
- STG $5.89
- PRLD $1.05
- Analyst Decision
- STG
- PRLD Strong Buy
- Analyst Count
- STG 0
- PRLD 2
- Target Price
- STG N/A
- PRLD $4.50
- AVG Volume (30 Days)
- STG 9.4K
- PRLD 611.2K
- Earning Date
- STG 11-22-2024
- PRLD 02-13-2025
- Dividend Yield
- STG N/A
- PRLD N/A
- EPS Growth
- STG N/A
- PRLD N/A
- EPS
- STG 4.57
- PRLD N/A
- Revenue
- STG $292,030,936.00
- PRLD $3,000,000.00
- Revenue This Year
- STG N/A
- PRLD N/A
- Revenue Next Year
- STG N/A
- PRLD N/A
- P/E Ratio
- STG $1.29
- PRLD N/A
- Revenue Growth
- STG N/A
- PRLD N/A
- 52 Week Low
- STG $4.25
- PRLD $0.80
- 52 Week High
- STG $12.55
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- STG 49.83
- PRLD 45.27
- Support Level
- STG $5.50
- PRLD $0.98
- Resistance Level
- STG $5.79
- PRLD $1.43
- Average True Range (ATR)
- STG 0.30
- PRLD 0.12
- MACD
- STG 0.03
- PRLD -0.02
- Stochastic Oscillator
- STG 65.83
- PRLD 14.14
About STG Sunlands Technology Group
Sunlands Technology Group is a provider of online post-secondary and professional education services in China. The company offers various degree- and diploma-oriented post-secondary courses through its online platforms. In addition, it provides online professional courses and educational content to help students prepare for professional certification exams and attain professional skills. The Group has one operating segment, which is the provision of online education services.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.